Expenses for the major four severe diseases tops KRW 7T
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.07.01 05:31:24
가나다라
0
An increase by 20% YoY…pharmaceutical expenses for rare·severe incurable diseases exceed KRW 3 trillion
About 27% of the total pharmaceutical expense…the importance of the post-management of high-cost drugs for cancer·rare diseases is discussed
Pharmaceutical expenses for the four major severe diseases exceeded KRW 7 trillion last year.
The four major severe diseases refer to cancer diseases, cerebrovascular disease, and rare·severe incurable diseases. Pharmaceutical expenses for this category have risen due to high-cost pharamceuticals.
Consequently, an analysis suggests that managing pharmaceuticals in this category is crucial for continuing the National Health Insurance.
The Health Insurance Review and Assessment Service (HIRA) published the '2023 Report on Reimbursement Claims for Pharmaceuticals Expenses' on June 27th. It indicates that the claim amount for the four major severe diseases last year was KRW 7.348
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)